ELISpot and Fluorospot Assay Market Set to Reach USD 528.30 Million by 2032, Driven by Immuno-Oncology Research and Diagnostic Innovation
SNS Insider Unveils Strategic Insights into the U.S. ELISpot and Fluorospot Assay Market's Rapid Growth—Valued at USD 79.68 Million in 2023—While the U.S. Commands Over 40% of the Global Share Amid Diagnostic Advancements in Immunology.
Austin, June 18, 2025 (GLOBE NEWSWIRE) -- ELISpot and Fluorospot Assay Market Size & Growth Analysis:
According to SNS Insider, the global ELISpot and Fluorospot Assay Market was valued at USD 290.92 million in 2023 and is projected to reach USD 528.30 million by 2032, growing at a CAGR of 6.85% during the forecast period of 2024–2032. The U.S. market alone was valued at USD 79.68 million in 2023, forecasted to climb to USD 138.33 million by 2032, with a CAGR of 6.32%.Get a Sample Report of ELISpot and Fluorospot Assay Market@ https://www.snsinsider.com/sample-request/5790
The growth trajectory is largely fueled by increasing applications in infectious disease diagnostics, cancer immunotherapy, and autoimmune disease research. As demand for highly sensitive immune response assays grows, these platforms are rapidly being adopted by hospitals, biotech firms, and academic labs.
Market Overview
The ELISpot and Fluorospot assays are gaining traction across immunological research and clinical diagnostics due to their precision in detecting immune responses. Widely utilized in vaccine development, autoimmune disease studies, and cancer immunotherapy, these assays are supported by the increasing demand for high-sensitivity diagnostics.
The U.S. remains a key contributor to market growth, benefiting from strong research funding, a highly developed healthcare infrastructure, and the presence of major industry players. Globally, market expansion is further driven by the rising incidence of chronic and infectious diseases and the growing adoption of personalized medicine. Technological advancements in assay analyzers and kits are expected to fuel additional market momentum throughout the forecast period.
Major Players Analysis Listed in this Report are:
Becton, Dickinson, and Company (BD ELISPOT Assay System, BD FluoroSpot Assay Kit)
U-CyTech biosciences (Human IFN-γ ELISPOT Kit, Monkey IL-4 FluoroSpot Kit)
Cellular Technologies Limited (CTL) (ImmunoSpot Human IFN-γ ELISPOT Kit, ImmunoSpot Human IL-2/IL-4 FluoroSpot Kit)
Mabtech AB (Human IFN-γ ELISpotPRO Kit, Human IL-2/IL-4 FluoroSpot Kit)
Abcam (Human IFN-γ ELISPOT Kit, Human IL-17A/IL-22 FluoroSpot Kit)
Oxford Immunotec (T-SPOT.TB Test, T-SPOT.COVID Test)
Bio-Techne Corporation (Human IFN-γ ELISpot Kit, Human IL-10/IL-12 FluoroSpot Kit)
Autoimmun Diagnostika GmbH (AID) (AID iSpot ELISPOT Plate Reader, AID iSpot Spectrum FluoroSpot Reader)
Lophius Biosciences GmbH (T-Track ELISPOT Kit, T-Track CMV FluoroSpot Kit)
Bio-Connect B.V. (Human TNF-α ELISPOT Kit, Human IL-5/IL-13 FluoroSpot Kit)
Thermo Fisher Scientific (Mabtech Human IFN-γ ELISpot Kit, Mabtech Human IL-2/IL-4 FluoroSpot Kit)
PerkinElmer Inc. (ATPlite Luminescence Assay System, LANCE Ultra TR-FRET Assay)
R&D Systems (Human IFN-γ ELISPOT Kit, Human IL-17/IL-22 FluoroSpot Kit)
Enzo Life Sciences (Human IFN-γ ELISPOT Kit, Human IL-4/IL-5 FluoroSpot Kit)
MilliporeSigma (Merck KGaA) (ELISpot Plate Reader System, FluoroSpot Multi-Analyte Assay Kit)
ImmunoDiagnostics Limited (Human IFN-γ ELISPOT Kit, Human IL-21/IL-22 FluoroSpot Kit)
ALPCO (Human IFN-γ ELISPOT Kit, Human IL-10/IL-12 FluoroSpot Kit)
RayBiotech Life, Inc. (Human IFN-γ ELISPOT Kit, Human IL-6/IL-8 FluoroSpot Kit)
Cell Sciences (Human IFN-γ ELISPOT Kit, Human IL-2/IL-5 FluoroSpot Kit)
ZellBio GmbH (Human IFN-γ ELISPOT Kit, Human IL-4/IL-10 FluoroSpot Kit)
ELISpot and Fluorospot Assay Market Report Scope
Report Attributes
Details
Market Size in 2023
USD 290.92 million
Market Size by 2032
USD 528.30 million
CAGR (2024–2032)
6.85%
U.S. Market 2023
USD 79.68 million
U.S. Forecast by 2032
USD 138.33 million
Base Year
2023
Forecast Period
2024–2032
Key Regional Coverage
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, Poland, Turkey, Rest of Europe), Asia Pacific (China, India, Japan, South Korea, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (UAE, Saudi Arabia, Qatar, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Segment Analysis
By Product
The assay kits segment captured the highest market share of 48.56% in 2023. This is due to the extensive use of assay kits in research and diagnostic applications. The need for high-sensitivity detection in immunological studies also contributes to the growth of this segment.
The segment of analyzers will be growing at the highest rate. The high demand for automated and high-throughput analyzers in research and laboratory settings is driving the growth of this segment. These analyzers improve accuracy and efficiency, leading to increasing demand in the market.
By Application
The diagnostic applications market held 65.41% of the market share in 2023. The growing incidence of infectious diseases, autoimmune diseases, and cancer has driven the demand for ELISpot and Fluorospot assays in clinical diagnostics. These assays provide accurate and early detection, leading to their popularity in diagnostic laboratories and healthcare facilities.
The research applications segment is expected to witness the most rapid growth. The growing emphasis on immunological research, vaccine discovery, and T-cell monitoring in cancer and infectious disease research is propelling the growth of this segment. Growing funding and advances in technology are also driving its rapid growth.
By End Use
The hospitals and clinical laboratories segment accounted for the largest share of 47.25% in 2023. The rising need for sophisticated diagnostic equipment in healthcare facilities, as well as the rising number of hospital-based research studies, has supported the application of ELISpot and Fluorospot assays in hospitals and clinical labs.
The biopharmaceutical and research institutes segment is expected to grow at the fastest rate. The growing investment in drug discovery and immunological research by academic institutions and pharmaceutical companies is fueling the demand for these assays in research settings.
For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https://www.snsinsider.com/request-analyst/5790
ELISpot and Fluorospot Assay Market Segmentation
By Product
Assay Kits
Analyzers
Ancillary Products
By Application
Research Applications
Diagnostics Applications
By End Use
Hospital and Clinical Labs
Academic and Research Institutes
Biopharmaceutical Company
Regional Insights
North America dominated the worldwide market in 2023 with a share of 36.25%, driven by its well-developed healthcare infrastructure, robust research culture, and high prevalence of adoption of next-generation diagnostic technologies. The United States is particularly prominent because of high government and private investment in immunology and infectious disease research.
The Asia-Pacific market is expected to have the highest growth rate until 2032. The major drivers include the growth of healthcare infrastructure, higher R&D spending, and an increasing prevalence of infectious diseases.
Recent Developments
February 2025: BD announced the separation of its Biosciences and Diagnostic Solutions business to enhance strategic focus and growth, potentially impacting its immunoassay product offerings, including ELISpot and Fluorospot assays.
April 2024: U-CyTech Biosciences was recognized as a leading company in the ELISpot and Fluorospot assay market, significantly contributing to immunological research and clinical diagnostics.
February 2024: Cellular Technology Limited (CTL) was identified as a major player in the ELISpot and Fluorospot assay market, with substantial contributions to assay development and distribution.
Statistical Insights and Trends Reporting
The United States accounted for approximately 40% of the global market share in 2023, driven by extensive research funding and strong healthcare infrastructure.
The total number of ELISpot and Fluorospot assay kits and analyzers deployed worldwide is expected to increase by 70% between 2024 and 2032.
The spending on immunology-based diagnostics, including ELISpot and Fluorospot assays, increased by 9.5% in 2023, reflecting the growing focus on early disease detection.
The use of ELISpot and Fluorospot assays in immuno-oncology research is expected to grow by 85% by 2032, driven by increasing interest in personalized medicine and T-cell monitoring.
Buy a Single-User PDF of ELISpot and Fluorospot Assay Market Analysis & Outlook Report 2024-2032@ https://www.snsinsider.com/checkout/5790
Table of Contents – Major Key Points
1. Introduction
2. Executive Summary
3. Research Methodology
4. Market Dynamics Impact Analysis
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence of Immune-related Diseases (2023)
5.2 Research and Clinical Adoption Trends, by Region (2023)
5.3 Assay Kit and Analyzer Volume, by Region (2020-2032)
5.4 Assay Kit and Analyzer Volume, by Region (2020-2032)
6. Competitive Landscape
7. ELISpot and Fluorospot Assay Market by Product
8. ELISpot and Fluorospot Assay Market by Application
9. ELISpot and Fluorospot Assay Market by End Use
10. Regional Analysis
11. Company Profiles
12. Use Cases and Best Practices
13. Conclusion
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company's aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
CONTACT: Contact Us: Jagney Dave - Vice President of Client Engagement Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK) Email: info@snsinsider.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Mainframe Modernization Services Market to Reach USD 76.16 Billion by 2032, Growing at a CAGR of 15.1%: Credence Research
PUNE, India, June 18, 2025 /PRNewswire/ -- According to a recent market analysis published by Credence Research, the global Mainframe Modernization Services Market is set to experience extraordinary growth, expanding from USD 21.5 billion in 2024 to USD 76.16 billion by 2032. This surge reflects a strong compound annual growth rate (CAGR) of 15.1% from 2025 to 2032. The report attributes this growth to the rising demand among enterprises to upgrade legacy infrastructure, reduce maintenance costs, and enhance agility through digital transformation. Credence Research notes that enterprises across sectors—particularly banking, insurance, healthcare, and government—are accelerating mainframe modernization to align with cloud-first strategies and future-ready IT ecosystems. The growing need for integration with modern digital platforms, along with advancements in automation, AI, and microservices architecture, is expected to further drive market momentum in the years ahead. Browse the report and understand how it can benefit your business strategy - Key Growth Determinants – Mainframe Modernization Services Market Demand for Operational Efficiency and Business AgilityOrganizations are under pressure to respond quickly to market changes and customer demands. Legacy mainframes often lack the flexibility and speed needed for modern operations. By modernizing these systems, companies can improve performance, streamline workflows, and increase adaptability—leading to faster decision-making and reduced time-to-market. A leading French bank achieved a 70% increase in operational performance and realized ROI within six months after migrating its mainframe application to a distributed Linux environment, demonstrating the tangible efficiency gains possible through modernization. In the retail sector, a major UK retailer modernized its mainframe environment, supporting critical operations like branch management and claims processing, by migrating to a cloud-based, open-standard platform. This shift enabled the organization to respond more adeptly to market demands and customer expectations, laying a robust foundation for future competitiveness. Accelerated Adoption of Cloud TechnologiesCloud computing plays a central role in modern IT infrastructure. Businesses are increasingly migrating mainframe workloads to public, private, or hybrid cloud environments to benefit from scalability, lower infrastructure costs, and seamless access to advanced tools. Mainframe modernization enables integration with cloud platforms, supporting cloud-native development and DevOps practices. Scalability and flexibility, allowing systems to expand or contract based on real-time needs. Lower infrastructure and maintenance costs, as cloud providers assume responsibility for hardware and security. Seamless integration with advanced tools, supporting cloud-native development and DevOps practices, which accelerates innovation and deployment cycles. For example, the aforementioned retailer transitioned from IBM z/OS to Java and PostgreSQL on Google Cloud Platform, aligning IT infrastructure with modern standards and reducing risks tied to legacy systems. Rising Costs and Risks of Legacy System MaintenanceMaintaining outdated mainframes is becoming increasingly expensive and complex. Hardware support is declining, and specialized skills are scarce, leading to higher operational risks and costs. Modernization allows companies to replace rigid legacy frameworks with more cost-effective, future-proof solutions. On average, legacy systems cost teams nearly $40,000 annually to maintain, with IT workers losing about 17 hours per week just on upkeep—almost half the workweek. In sectors like manufacturing and energy/utilities, annual maintenance costs can exceed $53,000 per worker. The scarcity of specialized mainframe skills, as many experts retire, further increases operational risks and costs. Modernization efforts can result in significant cost savings, with some organizations reporting up to 80% reductions in operational and maintenance expenses after transitioning to modern platforms. Enterprise-Wide Digital Transformation InitiativesIndustries such as banking, insurance, retail, and healthcare are investing in digital transformation to stay competitive. Mainframe modernization is a foundational step in this journey, enabling seamless data flow, real-time analytics, and integration with emerging technologies like AI, IoT, and blockchain—driving innovation and customer-centric solutions. Modernization enables seamless data flow, real-time analytics, and integration with emerging technologies like AI, IoT, and blockchain, which are critical for driving innovation and delivering customer-centric solutions. In the banking sector, moving high-volume document management off the mainframe to distributed platforms not only reduced technical debt but also ensured secure, modernized assets and uninterrupted service for end users. Retailers and other enterprises have validated that modernized environments support broader digital transformation, positioning organizations to adapt to future technological advancements and market shifts. Key Growth Barriers – Mainframe Modernization Services Market High Upfront Capital ExpenditureDespite long-term operational savings, mainframe modernization projects often require substantial initial investments. Costs can include new hardware, software licenses, cloud services, and skilled consulting. For many organizations—especially small and mid-sized enterprises—budget limitations may delay or restrict modernization plans, making it difficult to justify the transition financially in the short term. Complexity of Legacy Systems and ArchitectureMany mainframes have been in operation for decades, containing tightly coupled, business-critical applications with custom code and undocumented processes. Migrating these systems involves high technical risk, as even small errors can disrupt core operations. This complexity can slow down project execution, inflate costs, and make some organizations hesitant to modernize altogether. Lack of Skilled ResourcesThere is a dual talent gap in the market—experienced legacy system experts are retiring, while professionals skilled in modern platforms often lack mainframe-specific knowledge. This shortage hinders smooth migration and increases dependency on specialized service providers, driving up project costs and timelines. Regulatory and Compliance ChallengesOrganizations in regulated industries must maintain strict data security, auditability, and compliance standards during modernization. Ensuring that the new environment meets all legal and operational requirements can increase project complexity and duration, especially when dealing with cross-border data governance or financial regulations. Key Market Opportunities – Mainframe Modernization Services Market Expansion of Cloud-Native and Hybrid Cloud IntegrationEnterprises increasingly seek to integrate mainframe applications with cloud-native architectures. Modernization services that enable seamless migration to hybrid environments—leveraging containerization, microservices, and API-driven connectivity—stand to gain significant traction. Advent of AI-Driven AutomationIncorporating AI and machine learning into modernization workflows—such as code refactoring, workload optimization, and predictive maintenance—presents a compelling opportunity. Automated tools can accelerate migration timelines and reduce errors, unlocking cost savings and improved performance. Rise in Industry-Specific SolutionsTailored modernization offerings for regulated industries (like banking, healthcare, and utilities) are in demand. Services that embed compliance, data governance, and sector-specific integrations provide differentiated value and reduce adoption barriers for regulated customers. Modernization as a Service (MaaS) ModelsConsumption-based offerings—such as pay-as-you-go or managed modernization platforms—are gaining appeal. These flexible models reduce upfront investment and risk, enabling customers to modernize incrementally while benefiting from expert-managed support. M&A and Legacy System ConsolidationsAs organizations undergo mergers, acquisitions, or business restructuring, consolidating legacy mainframes becomes essential. Modernization services that simplify platform consolidation and rationalization across diverse environments are ripe for growth. Emergence of Microservices and API MonetizationTransforming monolithic mainframe workloads into modular microservices enables enterprises to create new digital offerings and monetization opportunities. Service providers that specialize in modern API frameworks and ecosystem integration can tap into this growing demand. Segmentation Based on Type Enterprise Size Modernization Cloud Migration Data Modernization Based on Enterprise Size Small and Medium Enterprise (SME's) Large Enterprise Based on End User IT and Telecom BFSI Retail & Healthcare Government Others Based on region North America Europe Asia Pacific Latin America Middle East & Africa Preview the report with a detailed sample and understand how it can benefit your business strategy. Request a free sample today - Regional Analysis – Mainframe Modernization Services Market North America, especially the United States, dominates the mainframe modernization market. Enterprises in banking, insurance, and telecom are prioritizing modernization to drive digital transformation and reduce legacy operational costs. Strong presence of major IT service providers and early adoption of cloud and AI-driven tools bolster regional growth. Additionally, favorable regulatory frameworks and large-scale corporate investments support robust spending in modernization services. Europe shows steady growth driven by government, healthcare, and financial institutions focused on data security and compliance. The European Union's evolving data privacy regulations (e.g., GDPR) compel organizations to modernize legacy systems to meet stringent standards. Hybrid cloud adoption is accelerating as businesses embrace modernization to support cross-border business use cases and achieve system consolidation. LATAM and MEA regions are gradually embracing modernization, with modern cloud and digital initiatives predominantly led by government and financial sectors. Public sector transformation initiatives and infrastructure upgrades in countries like Brazil, the UAE, and South Africa are creating fresh modernization opportunities. However, progress remains somewhat constrained by economic volatility, limited technical expertise, and budgetary limits. Credence Research's Competitive Landscape Analysis – Mainframe Modernization Services Market According to Credence Research, the competitive landscape of the Mainframe Modernization Services Market is characterized by a blend of global IT integrators, cloud hyperscalers, and niche modernization vendors. Leading players such as IBM, Accenture, Cognizant, and DXC Technology dominate the market with comprehensive service portfolios covering consulting, cloud migration, and platform modernization. Major cloud providers like Microsoft Azure and AWS are instrumental in enabling hybrid and cloud-native transformations. Indian IT giants including TCS, Infosys, and Wipro continue to expand their modernization offerings globally, leveraging domain-specific accelerators and cost-efficient delivery models. Meanwhile, specialized vendors like Rocket Software, Unisys, and TmaxSoft offer tailored solutions focused on rehosting, refactoring, and legacy integration with modern technologies such as AI and containerization. Regional players in Europe and Asia-Pacific are also strengthening their presence, supported by growing enterprise demand for industry-specific modernization and regulatory compliance. The market remains highly competitive and innovation-driven, with strategic partnerships and acquisitions playing a vital role in service differentiation and capability enhancement. Tailor the report to align with your specific business needs and gain targeted insights. Request Key Player Analysis TATA Consultancy Services Software AG Oracle Corporation Mphasis Ltd. Innova Solutions IBM Corporation Fujitsu Limited DXC Technology Dell EMC Cognizant Capgemini SE Atos Syntel Inc Accenture plc Recent Industry Developments April 2025 – AWS released version 4.8.0 of AWS Blu Age Runtime and Transformation Engines, featuring enhanced database transformation capabilities and performance improvements tailored for mainframe modernization projects. March 2025 – Astadia was recognized as a Leader in the ISG Provider Lens Mainframes – Services and Solutions 2025 report for its innovative use of GenAI agents to accelerate mainframe migration and modernization. January 2025 – BMC announced major enhancements to its BMC AMI suite, integrating hybrid AI functionalities that combine machine learning and generative AI to improve root cause analysis and operational efficiency. November 2024 – Cognizant and IBM partnered to launch the FinOps Center for Cloud Innovation, focused on transforming legacy applications through tools like Watsonx Code Assistant for Z, enabling hybrid cloud adoption and driving cloud cost optimization, ethical AI deployment, and multi-cloud efficiency. March 2024 – Accenture Federal Services collaborated with Microsoft to launch an end-to-end Cloud Modernization and Migration Factory on Microsoft Azure Government, designed for secure modernization across U.S. federal agencies, including those operating in the national security domain. March 2024 – Fujitsu partnered with AWS to support modernization of legacy mission-critical applications running on mainframes and UNIX servers, offering comprehensive assessment, migration, and modernization services for industries such as finance, retail, and automotive. March 2024 – Accenture Federal Services secured the U.S. Army's Enterprise Application Modernization and Migration (EAMM) contract, with a potential value of USD 127 million, to deliver large-scale cloud assessments, migrations, and application modernizations. Reasons to Purchase this Report: Gain a comprehensive understanding of the market through qualitative and quantitative analyses, considering both economic and non-economic factors, with segmentation and sub-segmentation details provided in terms of market value (USD Billion). Identify regions and segments expected to experience the fastest growth or dominate the market, with a detailed analysis of geographic consumption patterns and the factors driving or hindering market performance in each region. Stay informed about the competitive environment, with rankings of major players, recent product and service launches, partnerships, business expansions, and acquisitions from the past five years. Access detailed profiles of major market players, including company overviews, insights, product benchmarking, and SWOT analysis, to understand competitive advantages and market positioning. Explore the present and forecasted market landscape, with insights into growth opportunities, market drivers, challenges, and constraints for both developed and emerging regions. Benefit from Porter's Five Forces analysis and Value Chain insights to evaluate various market perspectives and competitive dynamics. Understand the evolving market scenario, including potential growth opportunities and trends expected in the coming years. Browse the report and understand how it can benefit your business strategy - Discover additional reports tailored to your industry needs Internet Security Market - Operator Training Simulation Market - Artificial Intelligence Voice Cloning Market - AI In Computer Vision Market - Air Purification Systems Market - Mainframe Market - Follow Us: About Us: Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 2000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. Contact Us Mitul DeanTower C-1105 , S 25, Akash Tower,Vishal Nahar, Pimple Nilakh, Haveli,Pune – 411027, Indiasales@ Logo - View original content to download multimedia: SOURCE Credence Research Inc. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
4 hours ago
- Business Wire
AM Best Revises Outlooks to Stable for Société Tunisienne de Réassurance
LONDON--(BUSINESS WIRE)-- AM Best has revised the outlooks to stable from negative and affirmed the Financial Strength Rating of B (Fair) and the Long-Term Issuer Credit Rating of 'bb' (Fair) of Société Tunisienne de Réassurance (Tunis Re) (Tunisia). The Credit Ratings (ratings) reflect Tunis Re's balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, limited business profile and marginal enterprise risk management (ERM). The revision of the outlooks to stable from negative reflects AM Best's expectation that Tunis Re's rating fundamentals will remain resilient against the backdrop of the elevated economic, political and financial system risks prevailing in Tunisia. Tunis Re's balance sheet strength is underpinned by its risk-adjusted capitalisation, as measured by Best's Capital Adequacy Ratio (BCAR), which was at the strongest level at year-end 2024. AM Best expects the company's risk-adjusted capitalisation to remain at the strongest level, supported by good organic capital generation, despite a relatively onerous dividend policy. The assessment factors in Tunis Re's conservative investment portfolio by asset class, and its concentration in Tunisia, where the company holds over 95% of its invested assets in line with regulatory requirements, which weighs on asset quality. Tunis Re has a track record of adequate operating performance, illustrated by a five-year (2020-2024) weighted average return-on-equity ratio of 8.2%. The company's earnings are derived largely from solid investment income, with a five-year weighted average net investment return (including gains/losses) of 7.8%. Tunis Re's underwriting performance is sound, underpinned by technical profits from its non-life portfolio, which translated into a five-year weighted average combined ratio of 96.0% (as calculated by AM Best). A partially offsetting rating factor is the potential volatility that foreign exchange gains and losses can introduce to Tunis Re's operating performance, as reported in recent years. Tunis Re's business profile assessment reflects its leading position in Tunisia and its good diversification into regional markets, with approximately 60% of gross written premium (GWP) generated outside Tunisia. Nonetheless, with GWP of TND 241 million (USD 76 million) in 2024, Tunis Re's scale remains limited in the global reinsurance market, which could hamper its ability to grow in a profitable manner due to competitive pressures. AM Best assesses Tunis Re's ERM as marginal, reflective of the high-risk operating environment in Tunisia, and the adverse impact it has on the company's risk profile. This press release relates to Credit Ratings that have been published on AM Best's website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best's Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings. For information on the proper use of Best's Credit Ratings, Best's Performance Assessments, Best's Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best's Ratings & Assessments.
Yahoo
4 hours ago
- Yahoo
First Trust Global Portfolios Management Limited Announces Distributions for certain sub-funds of First Trust Global Funds plc
LONDON, June 18, 2025--(BUSINESS WIRE)--First Trust Global Portfolios Management Limited ("FTGPM") announces the declaration of the quarterly distributions for the following sub-funds of First Trust Global Funds plc, ISIN Fund Name Frequency Dividend per Share IE000C75IMX8 First Trust Alerian Disruptive Technology Real Estate UCITS ETF Class B Quarterly $0.1602 (USD) IE00BF2FL590 First Trust Eurozone AlphaDEX® UCITS ETF Class B Quarterly 1.1724 (EUR) IE00BWTNM966 First Trust Germany AlphaDEX® UCITS ETF Class A Quarterly 0.5346 (EUR) IE00BD842Y21 First Trust Global Equity Income UCITS ETF Class B Quarterly $1.1549 (USD) IE00BKS2X200 First Trust Low Duration Global Government Bond UCITS ETF Class B Quarterly 0.0947 (GBP) IE00BKS2X317 First Trust Low Duration Global Government Bond UCITS ETF Class C Quarterly 0.1123 (EUR) IE000YVOQ2A3 First Trust SMID Rising Dividend Achievers UCITS ETF Class B Quarterly $0.0481 (USD) IE00BD9N0445 First Trust United Kingdom AlphaDEX® UCITS ETF Class B Quarterly 0.3162 (GBP) IE00BZBW4Z27 First Trust US Equity Income UCITS ETF Class A Quarterly $0.2676 (USD) IE00079WNSI6 First Trust US Equity Income UCITS ETF Class D Quarterly 0.1776 (GBP) IE00BWTNMB87 First Trust US Large Cap Core AlphaDEX® UCITS ETF Class B Quarterly $0.1699 (USD) Collectively the "Funds" and each, a "Fund". The Funds are advised by First Trust Advisors L.P. ("FTA"). The following dates apply to today's distribution declaration: Expected Ex-Dividend Date: 26 June 2025 Record Date: 27 June 2025 Payable Date: 11 July 2025 About First Trust Advisors L.P. FTA is a privately owned US-based financial services firm and is registered as an investment adviser with the United States Securities and Exchange Commission. FTA acts as adviser to a range of Irish domiciled UCITS funds under the First Trust Global Funds plc umbrella. The Funds' distributors are FTGPM and First Trust Global Portfolios Limited ("FT UK"), an affiliate of FTA. FTGPM is the management company of First Trust Global Funds plc umbrella. FT UK was established in December 2011 as a UK-based and UK Financial Conduct Authority ("FCA") regulated distributor and advisor. FTA, together with its affiliates, has total assets under management or supervision in excess of $268 billion as of at 31 May 2025. For more information, visit Risks The Funds' shares may change in value and may go down as well as up. You could lose money by investing in a Fund. You may not get back all of the money you invest. Market risk is the risk that a particular security, or shares of a fund in general may fall in value. Securities are subject to market fluctuations caused by such factors as general economic conditions, political events, regulatory or market developments, changes in interest rates and perceived trends in securities prices. Shares of a fund could decline in value or underperform other investments as a result. In addition, local, regional or global events such as war, acts of terrorism, spread of infectious disease or other public health issues, recessions, natural disasters or other events could have significant negative impact on a fund. Current market conditions risk is the risk that a particular investment, or shares of the fund in general, may fall in value due to current market conditions. As a means to fight inflation, the Federal Reserve and certain foreign central banks have raised interest rates and expect to continue to do so, and the Federal Reserve has announced that it intends to reverse previously implemented quantitative easing. Recent and potential future bank failures could result in disruption to the broader banking industry or markets generally and reduce confidence in financial institutions and the economy as a whole, which may also heighten market volatility and reduce liquidity. Ongoing armed conflicts between Russia and Ukraine in Europe and among Israel, Hamas and other militant groups in the Middle East, have caused and could continue to cause significant market disruptions and volatility within the markets in Russia, Europe, the Middle East and the United States. The hostilities and sanctions resulting from those hostilities have and could continue to have a significant impact on certain fund investments as well as fund performance and liquidity. The COVID-19 global pandemic, or any future public health crisis, and the ensuing policies enacted by governments and central banks have caused and may continue to cause significant volatility and uncertainty in global financial markets, negatively impacting global growth prospects. Recent and potential future bank failures could result in disruption to the broader banking industry or markets generally and reduce confidence in financial institutions and the economy as a whole, which may also heighten market volatility and reduce liquidity. There may be tracking difference between a Fund and the relevant underlying index due to the impact of annual Fund management fees. Therefore a Fund's return may not match the return of a Fund's benchmark. A Fund's holdings may be issued by companies concentrated in a particular industry or country. A Fund may invest in small capitalisation and mid capitalisation companies. Such companies may experience greater price volatility than larger, more established companies. As the Funds' investments may be denominated in currencies other than the Funds' currency, an investment in a Fund may expose you to currency risk. A Fund's Net Asset Value (NAV) is likely to have high volatility due to the portfolio composition and/or the index replication technique. As such, potential investors should be aware that a Fund's shares may change in value, and may do so in a volatile fashion; potential investors could lose money by investing in a Fund. Neither FTGPM nor any of its affiliates guarantees the performance or the future returns of a Fund. There is no guarantee that a Fund will declare dividends. For more details relating to risks of investing in the Funds, please refer to the "Risk Factors" section of the Fund's prospectus. Important Information This financial promotion is issued by FTGPM of Fitzwilliam Hall, Fitzwilliam Place, Dublin 2, D02 T292, Ireland. FTGPM is authorised and regulated by the Central Bank of Ireland (reference number CBI00185737). Nothing in this document constitutes an invitation, offer, solicitation or recommendation to engage in any investment activity including buying or selling any investment including any interest in the Fund. The Funds are open-ended sub-funds of the First Trust Global Funds plc (the "Company"), an umbrella UCITS fund with segregated liability between sub-funds, incorporated with limited liability as an investment company with variable capital under the laws of Ireland with UCITS registered number 514357. The Company is a recognised collective investment scheme (a "recognised scheme") for the purposes of section 264 of the Financial Services and Markets Act 2000, as amended ("FSMA"), of the United Kingdom. The Funds are not regulated by the FCA. Most of the protections provided by the UK regulatory system do not apply to the operation of the Funds and compensation will not be available under the UK Financial Services Compensation Scheme on its default. An investment in the Funds is speculative and may not be appropriate for all potential investors. FTGPM does not guarantee the performance of the shares of the Funds. The value of an investment and income from it can go down as well as up and may be affected by exchange rate variations. Investors may not get back the amount invested or lose their entire investment. Current tax levels and reliefs will depend on the nature of the holdings. Past performance is not a guide to future performance. The material in this document is not comprehensive and must therefore be read in conjunction with the Funds' Prospectus, which contains material information not contained herein, including the terms of investment and information regarding investment risks and restrictions, fees and expenses and conflicts of interests. Potential investors should pay particular attention to the risk disclosures in the Prospectus. No assurance can be given that the Funds' investment objective will be achieved or that the Funds will generate a positive return. Contact FTGPM or visit to obtain a Prospectus and/or Key Investor Information Document (available in English). Potential investors should conduct their own investigation and analysis of the Funds and consult its/their own professional tax, accounting, financial or other advisors as to the risks involved in making an investment. Potential investors should consider the Funds' investment objectives, risk, charges and expenses carefully before investing. Nothing contained herein constitutes investment, legal, tax or other advice nor is it to be solely relied on in making an investment or other decision. It is not an invitation to make an investment in the Funds nor does the information, recommendations or opinions expressed herein constitute an offer for sale of the Funds. Shares of the Funds are not available for sale in any state or jurisdiction in which such sale would be prohibited. The shares of the Funds have not been registered under the US Securities Act of 1933, as amended, and the Funds are not registered under the US Investment Company Act of 1940, as amended. Neither this material nor a Fund's shares are available to or suitable for US persons. Whilst every effort is made to ensure the accuracy of this information, no representation or warranty stated or implied is made or given by any persons as to the accuracy or completeness of the information contained in this document and no responsibility or liability is accepted for such information or opinion. "AlphaDEX®" is a registered trademark of First Trust Portfolios L.P. ("FTP"). FTP has obtained a patent for the AlphaDEX® stock selection methodology from the United States Patent and Trademark Office. The NASDAQ AlphaDEX® United Kingdom Index (the "UK Index") is a trademark of Nasdaq, Inc. ("Nasdaq") and has been licensed for use by First Trust Portfolios L.P., and sub-licensed for use by the Company. AlphaDEX® is a trademark owned by FTP. and has been licensed to Nasdaq for use in the name of the UK Index. The NASDAQ AlphaDEX® Eurozone Index (the "Eurozone Index") is a trademark of Nasdaq, and has been licensed for use by FTP, and sub-licensed for use by the Company. AlphaDEX® is a trademark owned by First Trust Portfolios L.P. and has been licensed to Nasdaq for use in the name of the Eurozone Index. The NASDAQ AlphaDEX® Germany Index (the "Germany Index") is a trademark of Nasdaq and has been licensed for use by FTP, and sub-licensed for use by the Company. AlphaDEX® is a trademark owned by FTP and has been licensed to Nasdaq for use in the name of the Germany Index. The NASDAQ AlphaDEX® US Large Cap Core Index (the "Large Cap Index") is a trademark of Nasdaq and has been licensed for use by FTP and sub-licensed for use by the Company. AlphaDEX® is a trademark owned by FTP. and has been licensed to Nasdaq for use in the name of the Large Cap Index. The NASDAQ US High Equity Income Index (the "US Equity Index") is a trademark of Nasdaq and has been licensed for use by FTP and sub-licensed for use by the Company. The NASDAQ Global High Equity Income Index (the "Global Index") is a trademark of Nasdaq and has been licensed for use by FTP, and sub-licensed for use by the Company. The NASDAQ US Small Mid Cap Rising Dividend Achievers™ Index (the "SMID Index") is a trademark of Nasdaq and has been licensed for use by FTP, and sub-licensed for use by the Company. Alerian®, S-NetworkSM and Alerian Disruptive Technology Real Estate IndexSM are service marks of Alerian and have been licensed for use by First Trust Advisors L.P. The First Trust Alerian Disruptive Technology Real Estate UCITS ETF ("DTRE") is not issued, sponsored, endorsed, sold or promoted by Alerian or its affiliates (collectively, "Alerian"), and Alerian makes no representation or warranty, express or implied, to the purchasers or owners of DTRE or any member of the public regarding the advisability of investing in securities generally or in DTRE particularly or the ability of the Alerian Disruptive Technology Real Estate Index (the "Index") to track general market performance. Alerian's only relationship to DTRE is in the licensing of the service marks and the Index, which is determined, composed, and calculated by Alerian without regard to First Trust Advisors L.P. or DTRE. Alerian is not responsible for and has not participated in the determination of the timing of, prices at, or quantities of DTRE issued by First Trust Advisors L.P. Alerian has no obligation or liability in connection with the issuance, administration, marketing, or trading of DTRE. The Funds are not sponsored, endorsed, sold or promoted by Nasdaq and Nasdaq makes no representation or warranty regarding the advisability of investing in the Funds or as to the result to be obtained by any person from use of the above identified indices in connection with the trading of the Funds. Source: First Trust Global Portfolios Management Limited View source version on Contacts Derek Fulton 44 (0) 203 195 7125
